1/3
12:20 pm
sgmo
Sangamo Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SGMO
Medium
Report
Sangamo Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SGMO
1/3
12:00 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
1/3
10:30 am
sgmo
Lost Money on Sangamo Therapeutics, Inc. (SGMO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
High
Report
Lost Money on Sangamo Therapeutics, Inc. (SGMO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
1/3
10:00 am
sgmo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation
High
Report
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation
1/2
09:05 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
High
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
1/2
06:00 pm
sgmo
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
High
Report
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
1/2
04:00 pm
sgmo
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
High
Report
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
1/2
03:05 pm
sgmo
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Medium
Report
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
1/2
10:15 am
sgmo
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation
1/2
09:24 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
1/1
05:32 am
sgmo
US Stocks Fall to Close Out Best Two-Year Stretch Since 1998 [Yahoo! Finance]
High
Report
US Stocks Fall to Close Out Best Two-Year Stretch Since 1998 [Yahoo! Finance]
12/31
06:21 pm
sgmo
Nippon-US Steel proposal, commodity prices in 2024: Market Domination [Yahoo! Finance Canada]
High
Report
Nippon-US Steel proposal, commodity prices in 2024: Market Domination [Yahoo! Finance Canada]
12/31
06:16 pm
sgmo
2024 recap, IPO market 2025 outlook: Market Domination Overtime [Yahoo! Finance]
High
Report
2024 recap, IPO market 2025 outlook: Market Domination Overtime [Yahoo! Finance]
12/31
05:53 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
High
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
12/31
02:59 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Jefferies Financial Group Inc. from $7.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Jefferies Financial Group Inc. from $7.00 to $3.00. They now have a "buy" rating on the stock.
12/31
10:48 am
sgmo
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact [Yahoo! Finance]
12/31
08:22 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Wells Fargo & Company from $3.00 to $2.00. They now have an "equal weight" rating on the stock.
Low
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Wells Fargo & Company from $3.00 to $2.00. They now have an "equal weight" rating on the stock.
12/31
05:26 am
sgmo
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug [Yahoo! Finance Canada]
High
Report
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug [Yahoo! Finance Canada]
12/30
04:15 pm
sgmo
Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
High
Report
Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
12/24
02:06 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
12/19
11:46 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
12/19
02:35 am
sgmo
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases [Yahoo! Finance]
Medium
Report
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases [Yahoo! Finance]
12/19
02:31 am
sgmo
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases [Yahoo! Finance]
12/19
02:30 am
sgmo
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Medium
Report
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
12/19
02:30 am
sgmo
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Medium
Report
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases